AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.

Brokerages have set a one year consensus price target of $3.50 for the company and are expecting that the company will post ($0.42) earnings per share for the current quarter, according to Zacks. Zacks has also given AEterna Zentaris an industry rank of 115 out of 265 based on the ratings given to related companies.

A number of brokerages recently commented on AEZS. Maxim Group increased their price target on AEterna Zentaris from $2.00 to $4.00 and gave the company a “buy” rating in a research report on Wednesday, July 19th. ValuEngine raised AEterna Zentaris from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.

An institutional investor recently raised its position in AEterna Zentaris stock. JPMorgan Chase & Co. raised its stake in AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) by 451.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 56,800 shares of the biopharmaceutical company’s stock after purchasing an additional 46,500 shares during the quarter. JPMorgan Chase & Co. owned 0.35% of AEterna Zentaris worth $120,000 at the end of the most recent reporting period. 3.11% of the stock is owned by hedge funds and other institutional investors.

AEterna Zentaris (AEZS) opened at $2.00 on Tuesday. AEterna Zentaris has a twelve month low of $0.78 and a twelve month high of $4.25.

ILLEGAL ACTIVITY NOTICE: “Brokerages Set $3.50 Target Price for AEterna Zentaris Inc. (AEZS)” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/11/14/brokerages-set-3-50-target-price-for-aeterna-zentaris-inc-aezs.html.

About AEterna Zentaris

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.